Characterization of Real-world Treatment Practices, Outcomes and Costs of Care in Patients with Hemophilia A and B: A Nationwide Finnish Cohort Study (HemoHEOR II)

Hemophilia is a rare, X-linked hereditary bleeding disorder caused by a deficiency or dysfunction of clotting factor VIII in hemophilia A (HA) or factor IX in hemophilia B (HB). The objective of this retrospective study is to assess the treatment outcomes and patterns of hemophilia patients, healthcare resource utilization, medication use and costs of care in Finland during 2012–2021.